Skip to main content Skip to main navigation menu Skip to site footer

Hubungan prostate specific antigen (PSA) dengan rasio stromal epitelial prostat pada pasien pembesaran prostat jinak

Abstract

Background: Benign Prostatic Hyperplasia is the most common benign lesion in male. Imbalance between proliferation and apoptotic is the cause of benign prostatic hyperplasia. Epithelial and stromal growths are associated with active proliferation that influenced by many factors and mechanism, including Epithelial Mesenchymal Transition. Prostate Specific Antigen (BPH) has role in prostate’s stromal epithelial ratio changing in patient with benign prostatic hyperplasia. Aim of the study is to determine the correlation between Prostate Specific Antigen with stromal epithelial ratio of prostate in patient with benign prostate hyperplasia.

Methods: 83 BPH patients, 50 to 80 years old with 20 to 80 grams prostates from ultrasound examination who underwent prostate trans uretra resection, had blood PSA examination and prostate specimens examination to evaluate the stromal epithelial ratio.  The data will be analize statistically.

Result: Prostate Specific Antigen has negative correlation with stromal epithelial ratio r -0,28 with p 0,01. PSA is autocrine for epithelial cells and paracrine for stromal cells and stimulate proliferations in both cells.

Conclusion: Prostate specific antigen has negative correlation with stromal epithelial ratio.

References

  1. Chugtai B, Lee R, Te A, Kaplan S. Role of Inflammation in Benign Prostatic Hyperplasia. Reviews in Urology. 2011;13(3):147-150.
  2. Cooperberg MR, Presti Jr JC, Shinohara K, Carroll PR. Neoplasms of the Prostate Gland, dalam McAninch JW, Lue TF. Smith and Tanagho’s General Urology 18th ed. The McGraw-Hill Companies. USA; 2013. p. 350-379.
  3. Bostanci Y, Kazzazi A, Momtahen S, Laze J, Djavan B. Correlation Between Benign Prostatic Hyperplasia and Inflammation. Current Opinion in Urology. 2013 ;23(1):5-10.
  4. Bradley L, Yaworsky PJ, Walsh FS. Myostatin as a therapeutic target for musculoskeletal disease. Cell Mol Life Sci. 2008;65:2119–2124.
  5. Chan S W. Pathology and Medical Therapy of Benign Prostatic Hyperplasia. Medical Buletin 2011;16:4-8.
  6. Cosimo DN, Gero K, Michael M. The Controversial Relationship Between Benign Prostatic Hyperplasia and Prostate Cancer: The Role of Inflammation, Eur Urol. 2011;60(1):106-17.
  7. Cunha GR, Ricke WA. A historical perspective on the role of stroma in the pathogenesis of benign prostatic hyperplasia. Differentiation. 2011;82(0):168-172.
  8. David AP, El-Nasir L. Prostate Cancer-Clinical and Scientific Aspects: Bridging The Gap. Philadelphia: Imperial College Press; 2003.
  9. David M, et al. Development, Molecular Biology, and Physiology of The Prostate [Online]. Abdominal Key. 2016. Tesedia di: https://abdominalkey.com/development-molecular-biology-and-physiology-of-the-prostate/.
  10. Duarsa GWK, Lesmana R, Mahadewa TGB. High Serum Prostate Specific Antigen as A Risk Factor for Moderate-Severe Prostate Inflammation in Patient with Benign Prostatic Hyperplasia. Bali Medical Journal. 2016;4(3):148-151. DOI:10.15562/bmj.v4i3.187.
  11. Fenely M, Mundy AR. The Prostate and Benign Prostatic Hyperplasia in The Scientific Basic of Urology 3rd edition United Kingdom. 2010; p. 316-334.
  12. Gravas S, et al. EAU Guidelines on Management of Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS). European Association of Urology; 2018.
  13. Mc Vary, et al. American Urological Association. Guideline. Management of Benign Prostatic Hyperplasia (BPH). American Urological Association Education and Research, Inc. USA; 2010.
  14. Mochtar CA, Umbas R, Soebadi DM. Clinical guideline benign prostate hyperplasia management (Benign Prostatic Hyperplasia/BPH) 2nd Edition. Jakarta: Indonesian Urological Association; 2015. p. 1-27.
  15. Nickel JC. (2015). Role of Prostatic Inflammation in the Clinical Presentation of Benign Prostatic Hyperplasia. European Urology Supplements. 2015;14(9):e1459–e1463.
  16. Nickel J. C. Inflammastion and Benign Prostatic Hyperplasia. Urol Clin North AM. 2008;35(1):109-115.
  17. Novara G, Galfao A, Berto RB, Ficarra V, Navarrete RV, Artibani W. Inflammation, Apoptosis and BPH: What is the evidence. J European Urology. 2006;5(4):401-409.
  18. Sorensen DL. One On One. The Journal of Supply Chain Management. 2000; 36(3):2–3.
  19. Sutkowski DM, et al. Growth Regulation of Stromal Cells by Prostate Specific Antigen. JNCI: Journal of National Cancer Institute. 1999;91(9):1663-1669.
  20. Tang J, Yang JC. Etiopathogenesis of Benign Prostatic Hyperplasia. Indian J Urol. 2009;25(3):312–317.
  21. Yalcinkaya FR, Gokcei A, Davarci M, et al. The Impact of NIH-IV Prostatitis on Early Post Operative Outcomes of Transurethral Resection of The Prostate in Patients with Symptomatic Benign Prostate Hyperplasia. Turk J Med Sci. 2011; 41:515-519.

How to Cite

Yustina, M., Duarsa, G. W. K., Oka, A. A. G., Yudiana, I. W., Santosa, I. K. B., & Mahadewa, T. G. (2019). Hubungan prostate specific antigen (PSA) dengan rasio stromal epitelial prostat pada pasien pembesaran prostat jinak. Medicina, 50(2). https://doi.org/10.15562/medicina.v50i2.721

HTML
50

Total
52

Share

Search Panel